Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks. Patients are evaluated weekly, and treatment continues for 2 weeks after resolution of symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end of treatment. Patients undergo follow-up at 2 weeks post-treatment.
Age
13–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
AIDS or other immunocompromising condition.
Candidal esophagitis.
Life expectancy of at least 2 months.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Evidence of non-candidal systemic fungal infection.
Abnormalities that may preclude esophagoscopy or endoscopy.
Unable to tolerate fluconazole.
Unable to give informed consent.
Enrollment in other experimental trials of approved or non-approved drugs or systemic compounds (unless approved by the Pfizer Clinical Monitor).
Other condition that would make patient unsuitable for enrollment.
Concurrent Medication:
Excluded:
Concomitant oral or topical antifungal agent.
Other experimental medications.
Patients with the following prior condition are excluded:
History of allergy to imidazoles or azoles.
Prior Medication:
Excluded:
Any oral or topical antifungal therapy within the past 3 days. Active use of illicit or illegal drugs.
